NASA selected 12 companies to provide services to its ISS program and five hail from just down the road of the program. Photo via nasa.gov

NASA has tapped a dozen companies to work on services for the International Space Station Program, and five come from the greater Houston region.

Houston-based Aegis Aerospace Inc., Cimarron Software Services, JES Tech, and Oceaneering were are all admitted to the program, as was Webster-based Leidos. The companies, along with the other seven selected, will provide research, engineering, and/or mission integration services to the ISS.

The program, which is based at NASA’s Johnson Space Center in Houston, is supported by a $478 million Research, Engineering & Mission Integration Services-2 or REMIS-2 contract, according to NASA.

The other selected companies are:

  • Axient Corp, based in Huntsville, Alabama
  • Consolidated Safety Services, based in Exploration Park, Florida
  • KBR Wyle, based in Fulton, Maryland
  • Metis, based in Albuquerque, New Mexico
  • Tec-Masters, based in Huntsville
  • Teledyne Brown Engineering, based in Huntsville
  • University of Alabama at Birmingham, Alabama

"The companies will provide spaceflight, ground hardware and software, sustaining engineering functions and services, payload facility integration, and research mission integration operations services," reads a NASA news release. "The majority of the work will take place at contractor facilities across the country. Services also may be required at other NASA centers, contractor or subcontractor locations, or vendor facilities as requirements warrant."

Each of the selected companies will receive a "multiple-award, indefinite-quantity contract with firm-fixed price and cost-plus-fixed-fee task orders." The contract officially began January 12 and extends through Sept. 30, 2030, with an option to extend through Sept. 30, 2032.

Half of the selected companies — Aegis, Cimarron, Consolidated Safety Services, JES Tech, Metis, and Tec-Masters — are small businesses and were selected as a part of the contract's small business reserve.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.